- N
Nitrase Therapeutics
- Regis B. Kelly
Regis B. Kelly, Ph.D., is the executive director of QB3, one of the four Governor Gray Davis Institutes for Science and Innovation. As executive director, Dr. Kelly helped launch two QB3-associated companies, QB3@953 now MBC Biolabs, a life sciences startup incubator, and Mission Bay Capital, a venture fund. As a result of his experiences, Dr. Kelly was appointed as senior advisor on innovation and entrepreneurship to the president of the university, Janet Napolitano. Prior to joining QB3 in 2004, Dr. Kelly served as executive vice-chancellor at UCSF and chairman of the department of biochemistry and biophysics. Dr. Kelly received an undergraduate degree in physics from the University of Edinburgh in Scotland and a Ph.D. in biophysics from the California Institute of Technology. Following a post-doctoral fellowship at Stanford, Dr. Kelly was an instructor in the department of neurobiology at Harvard.
Org chart
This person is not in the org chart
Teams
Offices
This person is not in any offices
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
